Other

Roche to pay $7.1 bn for Telavant Holdings

Swiss pharmaceutical group Roche said Monday it will pay $7.1 billion to buy Telavant Holdings, a group developing new treatments for inflammatory bowel diseases.

Immunology

Immune cells identified as 'metabolic factories' in the gut

A research team from MedUni Vienna has now demonstrated for the first time the central role of macrophages in the renewal of intestinal cells, which sheds light on the complex interplay between immune cells and tissue regeneration. ...

page 6 from 40